The medicines regulator will aim to take a more flexible licensing approach for the research and manufacture of rare disease therapies in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) is aiming to make sweeping changes to…
The medicines regulator will aim to take a more flexible licensing approach for the research and manufacture of rare disease therapies in the UK.
The Medicines and Healthcare products Regulatory Agency (MHRA) is aiming to make sweeping changes to…